[Immunohistochemical study on oncogene product ras p 21 in thyroid carcinoma].
The oncogene product ras p 21 was detected by an immunohistochemical procedure in 132 cases of thyroid carcinoma and 14 cases of normal thyroid. In addition, semiquantitative analysis using percentage of positive cells and a serially diluting test of the primary antibody were performed in papillary and follicular carcinoma, and its non-neoplastic counterparts. Papillary carcinoma showed identical results in the immunostaining and semiquantitative analysis between minute and advanced carcinoma. Papillary and follicular carcinoma exhibited significantly increased expression of ras p 21 in the cytoplasm, although the former showed much more enhanced expression of ras p 21 than that in the latter. The immunostaining for ras p 21 in papillary carcinoma differed clearly from non-neoplastic counterparts in which ras p 21 expression was moderately enhanced, although this difference was statistically disappeared between follicular carcinoma and its non-neoplastic counterparts. However, non-neoplastic tissue located close to these neoplasms showed more increased immunostaining for ras p 21 than that observed in the thyroid tissues remote from the neoplasm, and in normal thyroid. Squamous cell, anaplastic and medullary carcinoma demonstrated non or poor expression of ras p 21. These results suggested that ras p 21 had some effects on papillary and follicular carcinoma, and the effects of oncogene product on the neoplasm and non-neoplastic counterparts differed considerably depending upon a histological type of thyroid carcinoma.
Mochizuki
Y
Y
Nakayama
I
I
Noguchi
S
S
D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000032:analysis* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D015689:Oncogene Protein p21(ras) / Q000032:analysis* / Q000276:immunology; D013964:Thyroid Neoplasms / Q000032:analysis* / Q000473:pathology
D015689:Oncogene Protein p21(ras)